Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jacob A. Jochum"'
Autor:
Jacob A. Jochum, Mina Samir Erian Hanna, Tanios Bekaii-Saab, Wen Wee Ma, Henry C. Pitot, Jessica L Mitchell, Rachel A. Eiring, Aminah Jatoi, Caleb J. Smith, Thorvardur R. Halfdanarson, Kathryn D. Cook, Zhaohui Jin
Publikováno v:
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. 21(2)
Background Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment for metastatic pancreas cancer. It is unclear, however, whether patients who had received irinotecan derive benefit. Methods Medical records of metastatic pancreas can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::592899aa8265d8b16b0b7a342756ee2e
https://pubmed.ncbi.nlm.nih.gov/33468394
https://pubmed.ncbi.nlm.nih.gov/33468394
Autor:
Zhaohui Jin, Jacob A. Jochum, Henry C. Pitot, Harry H. Yoon, Aminah Jatoi, Daniel S. Childs, Rachel A. Eiring
Publikováno v:
Support Care Cancer
PURPOSE. Falls can occur in older cancer patients, but few studies have examined falls in an age-unspecified group of patients with locally advanced esophageal cancer. Because these patients are often administered neuropathy-inducing agents, are weak
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::366c7a4ddcdd94a47d9c3d0fc16e0c66
https://pubmed.ncbi.nlm.nih.gov/32447502
https://pubmed.ncbi.nlm.nih.gov/32447502
Autor:
Leah C Soderberg, Vanessa Wookey, Jessica L. Mitchell, Jacob A. Jochum, Nguyen H. Tran, Thorvardur Ragnar Halfdanarson, Joleen M. Hubbard, Rondell P. Graham, Kellie Leanne Mathis, Amit Mahipal, Zhaohui Jin
Publikováno v:
Journal of Clinical Oncology. 40:192-192
192 Background: Rectal cancer treatment paradigm has been evolving over time. Historically, for locally advanced rectal cancer, standard therapy (ST) consisted of neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy. Recently, tot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::942910619a490df5c034c85ba5e33126
https://doi.org/10.1200/jco.2022.40.4_suppl.192
https://doi.org/10.1200/jco.2022.40.4_suppl.192
Autor:
Tanios Bekaii-Saab, Mina Samir Erian Hanna, Jessica L Mitchell, Wen Wee Ma, Rachel A. Eiring, Aminah Jatoi, Caleb J. Smith, Zhaohui Jin, Henry C. Pitot, Thorvardur R. Halfdanarson, Kathryn D. Cook, Jacob A. Jochum
Publikováno v:
Journal of Clinical Oncology. 39:402-402
402 Background: Pancreas cancer is an aggressive malignancy with limited therapeutic options. Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment, and current guidelines recommend its use in the absence of prior irinotecan. This s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb48c5da6282be24486eeb0b2b4c36ff
https://doi.org/10.1200/jco.2021.39.3_suppl.402
https://doi.org/10.1200/jco.2021.39.3_suppl.402